Detalhe da pesquisa
1.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116523
2.
FLT3 inhibitors added to induction therapy induce deeper remissions.
Blood
; 135(1): 75-78, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722002
3.
Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
Leuk Lymphoma
; 64(13): 2156-2164, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715313
4.
Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study.
Leuk Res
; 125: 107006, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580877
5.
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
J Clin Oncol
; 41(9): 1714-1724, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669146
6.
Nonoperative vs Operative Management of Uncomplicated Acute Appendicitis: A Systematic Review and Meta-analysis.
JAMA Surg
; 157(9): 828-834, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895073
7.
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Transplant Cell Ther
; 27(2): 153-162, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33017662
8.
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Leukemia
; 37(6): 1379-1383, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085610